NCT00294346

Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder

A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Social Anxiety Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (planned)
• Sponsor: Avera Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder. AV608 is an NK-1 receptor antagonist that exhibits central nervous system activity after oral administration. The study will compare AV608 to placebo (a medically inactive substance) to see if AV608 helps the symptoms of Social Anxiety Disorder. Eligible subjects will be assigned by chance to take either AV608 or placebo for 12 weeks. During the study, subjects will be asked about their overall health and mood and their Social Anxiety Disorder.

Conditions

• Social Phobia

Interventions

Type	Name	Description
DRUG	AV608

Timeline

• Start date: 2006-02-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2006-02-22
• Last updated: 2008-02-25

Locations

15 sites across 1 country: United States